Wolfe Research analyst Mike Polark lowered the price target on ResMed (NYSE: RMD) to $180.00 (from $230.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE